News >

Expert Anticipates Exciting Advances in Adjuvant Melanoma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Mar 21, 2017

Jason J. Luke, MD

Jason J. Luke, MD

Experts in the melanoma field are aware of the rapid progress made over the last 5 years, but the explosion of ongoing research—especially with combination regimens—signals that the work is far from done.

State of the Science Summit on Melanoma and Immuno-Oncology, lectured on adjuvant therapy for patients with melanoma, as well as the future of targeted agents and immunotherapy. In an interview during the meeting, he explained these topics a few steps further, sharing what’s next for the ever-evolving field.

OncLive: What is important to highlight regarding adjuvant therapy in melanoma?

Luke: Adjuvant therapy for melanoma is becoming more exciting with the approval of ipilimumab a few years ago and, now, the readout of an improvement in OS for patients. We now, for the first time, truly have a drug that improves the overall survival (OS) and outcomes for patients. 

It certainly is not the case that all patients should get ipilimumab for stage III melanoma, but rather a discussion should be given about risks and benefits. This is because there is about a one-third chance that a patient will get severe toxicity from ipilimumab, all which is reversible. However, that’s under consideration—especially for patients at a more advanced stage. 

Are there other agents being studied in the adjuvant setting?

There is an explosion of clinical trials that are ongoing now. We haven’t had the readouts yet, but clinical trials are going to be coming soon with results. These include comparisons of CTLA-4 blockade with ipilimumab as compared with PD-1 blockade, either with nivolumab or pembrolizumab (Keytruda). The gut feeling is that most oncologists think that those will be positive trials and, given the preferred safety profile of PD-1 antibodies, we’re excited about that to eventually move into the adjuvant setting. 

Beyond that, there’s even some discussion around combination immunotherapy with CTLA-4 and PD-1 immunotherapy in the adjuvant setting. That will be a rather toxic adjuvant therapy, so I’m sure there will be much debate about that.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x